Completed PHASE2 INTERVENTIONAL 1-arm NCT02890602

Erythropoietin for Management of Anemia Caused by Chemotherapy

A Phase Ⅱ Study of Erythropoietin for Management of Anemia Caused by Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Sponsor: Kosin University Gospel Hospital

Conditions Diffuse Large B-cell Lymphoma

Interventions Darbepoetin alfa R-CHOP

Updated 7 times since 2017 Last updated: Feb 19, 2020 Started: Sep 1, 2012 Primary completion: Nov 28, 2017 Completion: Dec 7, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diffuse Large B-cell Lymphoma and is currently completed. Kosin University Gospel Hospital leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2018 — Mar 2020 [monthly]

Active Not Recruiting PHASE2

▶ Show 2 earlier versions

Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kosin University Gospel Hospital

Data source: Kosin University Gospel Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.